

Literatur Kapitel 10 - Kardiovaskuläre Prävention

10.1. Management des Cholesterins

1. Kochen MM. Statine für alle über 50: Bedenkliche Auswirkungen der neuen amerikanischen Cholesterin-Leitlinie. Zeitschrift für Allgemeinmedizin 2015; (91):2 [Stand: 16.07.2018]. Verfügbar unter: <https://www.online-zfa.de/archiv/ausgabe/artikel/zfa-2-2015/48316-statine-fuer-alle-ueber-50-bedenkliche-auswirkungender-neuen-amerikanischen-cholesterin-leit/>.
2. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017; 70(14):1785–822. doi: 10.1016/j.jacc.2017.07.745.
3. Ravnskov U, Hrsg. Mythos Cholesterin: Die zehn größten Irrtümer. 2., erg. Aufl. Stuttgart: Hirzel; 2004.
4. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Arbeitspapier: Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin [Stand: 16.07.2018]. Verfügbar unter: https://www.iqwig.de/download/Arbeitspapier_Nutzenbewertung_der_Statine_unter_besonderer_Beruecksichtigung_von_Atorvastatin_.pdf.
5. © arznei-telegramm Arzneimitteldatenbank. Bewertung: Simvastatin; 2015 [Stand: 16.06.2018]. Verfügbar unter: <https://www.arznei-telegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Simvastatin&ord=uaw>.
6. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. The Lancet 2010; 376(9753):1658–69. doi: 10.1016/S0140-6736(10)60310-8.
7. Catapano AL, Graham I, Backer G de, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39):2999–3058. doi: 10.1093/eurheartj/ehw272.
8. © arznei-telegramm. LDL-ZIELWERTE ODER FIXE DOSIS? ... Aktuelles zur Strategie der Statintherapie; 2018 [Stand: 16.06.2018]. Verfügbar unter: https://www.arznei-telegramm.de/html/htmlcontainer.php3?produktid=052_01&artikel=1806052_01k.
9. Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I et al. Chro-notherapy versus conventional statins therapy for the treatment of hyperlipidaemia. Cochrane Database Syst Rev 2016; 11:CD009462. doi: 10.1002/14651858.CD009462.pub2.
10. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev 2014; (11):CD010254. doi: 10.1002/14651858.CD010254.pub2.
11. © arznei-telegramm Arzneimitteldatenbank. Bewertung: Rosuvastatin; 2016 [Stand: 16.06.2018]. Verfügbar unter: <https://www.arznei-telegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Rosuvastatin&ord=uaw>.
12. Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for lowering lipids. Cochrane Database Syst Rev 2018; 3:CD012282. doi: 10.1002/14651858.CD012282.pub2.
13. Conforti A, Magro L, Moretti U, Scotto S, Motola D, Salvo F et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf 2006; 29(12):1163–72.
14. Streetman DS, Stout SM. Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? CMAJ 2015; 187(3):163–5. doi: 10.1503/cmaj.150030.
15. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015; (10):CD009580. doi: 10.1002/14651858.CD009580.pub2.
16. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016; 11:CD009753. doi: 10.1002/14651858.CD009753.pub2.
17. © arznei-telegramm Arzneimitteldatenbank. Bewertung: Ezetimib; 2016 [Stand: 16.06.2018]. Verfügbar unter: <https://www.arznei-telegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Ezetimib&ord=uaw>.
18. Savarese G, Ferrari GM de, Rosano GMC, Perrone-Filardi P. Safety and efficacy of ezetimibe: A meta-analysis. Int J Cardiol 2015; 201:247–52. doi: 10.1016/j.ijcard.2015.08.103.
19. Pharmainformation. Oligonukleotid-basierte Arzneitherapie: ein neues molekulares Konzept; 2017 [Stand: 17.07.2018]. Verfügbar unter: <https://www.i-med.ac.at/pharmakologie/pharmainfo/info32-3.html#oligo>.
20. Infotool zum Erstattungskodex. Repatha; 2015 [Stand: 17.07.2018]. Verfügbar unter: <https://www.sozialversicherung.at/oeko/views/detail.xhtml?pharmaNumber=4221264>.
21. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18):1713–22. doi: 10.1056/NEJMoa1615664.
22. © arznei-telegramm Arzneimitteldatenbank. Bewertung: Evolocumab; 2018 [Stand: 16.06.2018]. Verfügbar unter: <https://www.arznei-telegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Evolocumab&ord=uaw>.

23. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease: John Wiley & Sons, Ltd. (The Cochrane Library). Verfügbar unter: <http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011748.pub2/full>.
24. Grunert D. Hypercholesterinämie: Neuer PCSK9-Inhibitor Inclisiran senkt LDL langfristig [Stand: 17.07.2018]. Verfügbar unter: <https://www.aerzteblatt.de/archiv/191826/Hypercholesterinaemie-Neuer-PCSK9-Inhibitor-Inclisiran-senkt-LDL-langfristig>.
25. Wang Y, Wang J, Wang S. Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials. *Am J Cardiovasc Drugs* 2018; 18(4):271–82. doi: 10.1007/s40256-018-0270-7.
26. Neuner-Jehle S. Kritischer Blick auf die Prävention – wann ist weniger mehr?; 2010 PrimaryCare 2010;10: Nr.19.
27. Graham Walker and The NNT Group. Homepage – TheNNT [Stand: 17.07.2018]. Verfügbar unter: <http://www.thennt.com/>.

10.2. Diät zur kardiovaskulären Prävention

1. © arznei-telegramm. FETTMODIFIZIERTE DIÄT ZUR KARDIOVASKULÄREN PRÄVENTION - WAS IST BELEGT?; 2010 [Stand: 17.07.2018]. Verfügbar unter: https://www.arznei-telegramm.de/html/htmlcontainer.php3?produktid=019_01&artikel=1002019_01k.
2. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev* 2015; (6):CD011737. doi: 10.1002/14651858.CD011737.
3. Clar C, Al-Khudairy L, Loveman E, Am Kelly S, Hartley L, Flowers N et al. Low glycaemic index diets for the prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2017; 7:CD004467. doi: 10.1002/14651858.CD004467.pub3.
4. Am Kelly S, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L et al. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2017; 8:CD005051. doi: 10.1002/14651858.CD005051.pub3.
5. Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2016; (1):CD011472. doi: 10.1002/14651858.CD011472.pub2.
6. Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper L, Rees K. Omega 6 fatty acids for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2015; (11):CD011094. doi: 10.1002/14651858.CD011094.pub2.
7. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega 3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2018:CD003177.
8. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013; 368(14):1279–90. doi: 10.1056/NEJMoa1200303.
9. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med* 2015; 128(3):229–38. doi: 10.1016/j.amjmed.2014.10.014.
10. Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M et al. 'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2013; (8):CD009825. doi: 10.1002/14651858.CD009825.pub2.
11. Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di Angelantonio E et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. *BMJ* 2011; 343:d4488.
12. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev* 2012; (3):CD007176. doi: 10.1002/14651858.CD007176.pub2.

10.3. Homozystein

1. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev* 2017; 8:CD006612. doi: 10.1002/14651858.CD006612.pub5.
2. Kochen MM. Primärprävention des Schlaganfalls: Die Wiedergeburt der Folsäure. *Zeitschrift für Allgemeinmedizin* 2014; (91 (6)):244–6 [Stand: 18.07.2018]. Verfügbar unter: https://www.online-zfa.de/fileadmin/user_upload/Heftarchiv/ZFA/article/2015/06/B808CC96-CD12-48D2-960E-264C42D26F79/B808CC96CD1248D2960E264C42D26F79_benefit_schlaganfall_1_original.pdf.

10.4. Colchicin

1. Kochen MM. Niedrigdosierte Colchizin in der Sekundärprophylaxe kardiovaskulärer Erkrankungen. Zeitschrift für Allgemeinmedizin 2014; (90 (1)):5 [Stand: 18.07.2018]. Verfügbar unter: https://www.online-zfa.de/fileadmin/user_upload/Heftarchiv/ZFA/article/2014/01/85BE6380-0D12-47D6-98EE-7635E45B5C87/85BE63800D1247D698EE7635E45B5C87_benefit_colchizin_1_original.pdf.
2. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61(4):404–10. doi: 10.1016/j.jacc.2012.10.027.
3. Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev 2016; (1):CD011047. doi: 10.1002/14651858.CD011047.pub2.
4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377(12):1119–31. doi: 10.1056/NEJMoa1707914.
5. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166(2):199–207. doi: 10.1016/j.ahj.2013.03.018.
6. Di Pietro M, Filardo S, Santis F de, Mastromarino P, Sessa R. Chlamydia pneumoniae and oxidative stress in cardiovascular disease: state of the art and prevention strategies. Int J Mol Sci 2014; 16(1):724–35. doi: 10.3390/ijms16010724.

10.5. Weitere kardiovaskuläre Risikofaktoren

1. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17):1811–21. doi: 10.1056/NEJMr0800885.
2. Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol 2016; 213:4–7. doi: 10.1016/j.ijcard.2015.08.110.
3. Giannopoulos G, Angelidis C, Devereux S. Gout and arrhythmias: In search for causation beyond association. Trends Cardiovasc Med 2018. doi: 10.1016/j.tcm.2018.06.004.
4. Kei A, Koutsouka F, Makri A, Elisaf M. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72(1). doi: 10.1111/ijcp.13048.
5. Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford) 2018; 57(suppl_1):i47–i50. doi: 10.1093/rheumatology/kex432.
6. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.
7. Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB et al. Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int 2014; 25(8):2047–56. doi: 10.1007/s00198-014-2732-3.
8. Cormick G, Ciapponi A, Cafferata ML, Belizán JM. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev 2015; (6):CD010037. doi: 10.1002/14651858.CD010037.pub2.
9. Rautiainen S, Wang L, Manson JE, Sesso HD. The role of calcium in the prevention of cardiovascular disease--a review of observational studies and randomized clinical trials. Curr Atheroscler Rep 2013; 15(11):362. doi: 10.1007/s11883-013-0362-4.
10. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309(1):71–82. doi: 10.1001/jama.2012.113905.
11. Kaur A, Johnston DG, Godsland IF. Does metabolic health in overweight and obesity persist? - Individual variation and cardiovascular mortality over two decades. Eur J Endocrinol 2016; 175(2):133–43. doi: 10.1530/EJE-16-0095.
12. Dobson R, Burgess MI, Sprung VS, Irwin A, Hamer M, Jones J et al. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes (Lond) 2016; 40(1):153–61. doi: 10.1038/ijo.2015.151.
13. Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control 2006; 15(6):472–80. doi: 10.1136/tc.2006.016246.
14. Hackshaw A, Morris JK, Boniface S, Tang J-L, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360. doi: 10.1136/bmj.j5855.